Pharmaceutical company AstraZeneca has announced the positive results of an antibody drug trial.
The company has said this drug has been found effective in the prevention of symptomatic Covid-19. The company hopes that this antibody drug will offer an alternative to people who are afraid of vaccination and those people.
The trial included 5,197 people who were not affected by the Covid-19.
The results showed that the drug reduced the risk of developing symptomatic disease by 77%, while no volunteer had a serious illness.
An older trial of the drug AZD7442 in June found that its use reduced the risk of developing symptomatic disease by only 33%.
Researcher Maureen Levine, who was involved in the new trial, said the data showed that a single dose of the drug, acting at lightning speed, effectively prevented symptomatic disease.
He said the encouraging results of the trial indicated that AZD7442 would help restore normal life to the people.
He said the drug is expected to be used in combination with vaccines to give people more protection for up to 12 months.
The trial included adults who did not tolerate vaccines or had a weakened immune response, which increased their risk of disease.